Clinical Trial Update: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Genetically Engineered Anti-CD19/CD20/CD22 CAR T-cells for relapsed or refractory lymphoid malignancies; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Prolymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• High-grade B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Transformed Chronic Lymphocytic Leukemia

Drugs mentioned

• Genetically engineered anti-CD19/CD20/CD22 CAR T-cells (CAR T-cell therapy targeting CD19, CD20, and CD22)

Snippet

Sponsor: Sumithira Vasu | Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING